Geojit Investments has reaffirmed its HOLD rating on HDFC Bank Limited, citing resilient earnings momentum, improving asset quality, and disciplined cost management, while flagging concerns around
News in Focus
Featured, India Business, Analyst View, Stock Markets, HealthCare, India, Max Healthcare, Prabhudas Lilladher
Max Healthcare Institute reported a subdued Q3FY26, with EBITDA growth constrained by seasonal softness, temporary operational disruptions, and pre-commissioning costs linked to capacity expansion.
Mahanagar Gas Ltd (MGL) delivered a largely in-line operational performance in the December quarter, reinforcing Axis Securities’ conviction in the company’s medium-term growth trajectory.
Axis Securities has maintained a BUY recommendation on Star Cement Limited, reaffirming confidence in the company’s expanding capacity base, margin trajectory, and long-term demand outlook across E
Not long ago, accessing digital services meant sitting down at a computer, opening a browser, and navigating through multiple pages. Today, that routine feels outdated.
Featured, India Business, Analyst View, Stock Markets, IDBI Capital, India, Steel Sector, Tata Steel
IDBI Capital has reiterated its HOLD rating on Tata Steel following a better-than-expected Q3FY26 performance, anchored by robust volume growth in India even as realizations softened.
Main Regional Stories
ICICI Securities has reiterated a BUY call on Uno Minda following a robust Q3FY26 performance that underscored the company’s ability to outpace industry growth amid structural tailwinds.
Featured, India Business, Analyst View, ICICI Securities, India, Mazagon Dock Shipbuilders, Public Sector
Mazagon Dock Shipbuilders continues to demonstrate resilient execution across its naval programs, even as its order book gradually normalizes after several years of elevated backlog.
Hero MotoCorp’s Q3FY26 performance reinforces the durability of its core business at a time when the company is simultaneously investing heavily in electric mobility and global scale-up.
Jubilant Pharmova’s December quarter results reinforce a steady growth narrative even as near-term margin pressures temper earnings momentum.
